Item 7.01. Regulation FD Disclosure.

On January 29, 2023, Sorrento Therapeutics, Inc. (the "Company") posted under the "Investors" section of its website at www.sorrentotherapeutics.com a document containing information and responses to frequently asked questions (the "FAQ Disclosure") regarding the previously disclosed stock dividend consisting of an aggregate of 76,000,000 shares of common stock, par value $0.0001 per share, of Scilex Holding Company ("Scilex") held by the Company. A copy of the FAQ Disclosure is (i) furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference and (ii) also posted under the "Investors" section of Scilex's website at www.scilexholding.com. On January 29, 2023, the Company issued a press release regarding the FAQ Disclosure. A copy of the press release is furnished herewith as Exhibit 99.2 to this Current Report on Form 8-K.

The information under this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 and Exhibit 99.2 hereto, is being furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Securities Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing. This report will not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.

Item 9.01. Financial Statements and Exhibits.





(d) Exhibit.



  99.1         FAQ Disclosure, dated January 29, 2023.
  99.2         Press Release, dated January 29, 2023.
104          Cover Page Interactive Data File, formatted in Inline Extensible
             Business Reporting Language (iXBRL).

© Edgar Online, source Glimpses